Welcome to our dedicated page for Replimune Group news (Ticker: REPL), a resource for investors and traders seeking the latest updates and insights on Replimune Group stock.
Replimune Group Inc (REPL) is a clinical-stage biotechnology leader advancing oncolytic immunotherapies through its proprietary RPx platform. This page provides investors and researchers with timely updates on clinical trials, regulatory milestones, and corporate developments.
Access a centralized repository of press releases, financial reports, and scientific updates related to Replimune’s pipeline candidates RP1, RP2, and RP3. Track progress in viral gene therapy for solid tumors, partnership announcements, and strategic initiatives shaping the future of cancer treatment.
Key updates include clinical trial results, FDA designations, collaboration agreements, and financial performance. Our curated news feed ensures you stay informed about breakthroughs in immunogenic cell death research and combination therapy strategies.
Bookmark this page for streamlined access to Replimune’s latest developments. Check regularly for authoritative updates on innovations in oncolytic immunotherapy and their implications for oncology care.
Replimune Group announced promising data on its oncolytic immuno-gene therapies RP1 and RP2 at the AACR 2021 Annual Meeting. Key findings include increased infiltration of CD8+ T cells and PD-L1 expression in patients treated with RP1 and RP2, suggesting robust systemic immune activation. Pre-clinical studies also indicated potent anti-tumor activity driven by GALV-GP R- expression. The data support RP1 and RP2's potential as effective treatment options, particularly in hard-to-treat cancers, enhancing tumor destruction while minimizing off-target effects.
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company focused on oncolytic immuno-gene therapies, will present two posters at the AACR Annual Meeting 2021, held virtually from April 10-15 and May 17-21, 2021. The presentations include:
- LB180: Clinical biomarker studies on oncolytic HSV (RP1 and RP2) combined with nivolumab, scheduled for April 10 at 8:30 am EDT.
- 1917: Immunomodulatory effects of a novel herpes simplex virus platform with anti PD-1 therapy, also on April 10 at 8:30 am EDT.
Both posters will be available on-demand from April 10.
Replimune Group, Inc. (Nasdaq: REPL) announced participation in three upcoming virtual investor conferences. The H.C. Wainwright Global Life Sciences Conference will be held on March 9-10, 2021, featuring a live presentation on March 9 at 7:00 am ET. The Barclays Global Healthcare Conference takes place on March 11, 2021, with a fireside chat scheduled for 9:10 am ET. Lastly, the 33rd Annual Roth Conference is set for March 17, 2021, at 1:30 pm ET. A webcast of the Barclays presentation will be available for replay on Replimune's website for 90 days.
Replimune Group, Inc. (NASDAQ: REPL) announced that CEO Philip Astley-Sparke will present at the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 8:40 AM ET. The presentation will be available via webcast on Replimune's website, with a replay accessible for 90 days post-conference.
Founded in 2015 and based in Woburn, Massachusetts, Replimune is developing oncolytic immuno-gene therapies using its proprietary Immulytic™ platform, aiming to enhance immune responses to cancer treatments.
Replimune Group (NASDAQ: REPL) reported its fiscal third quarter results for 2020, revealing a net loss of $21.8 million, up from $16.2 million a year prior. The company highlighted its progress in advancing its clinical candidates, particularly RP1, RP2, and RP3, with several studies ongoing and initial data expected throughout 2021. Additionally, Replimune's cash position stands at $493.3 million, extending its runway through the second half of 2024. However, the company noted that COVID-19 has impeded patient enrollment in clinical trials.
Replimune Group Inc. (NASDAQ: REPL) announced significant progress in its oncolytic immuno-gene therapy programs. Key developments include ongoing trials for RP1 in combination with Opdivo for anti-PD1 failed melanoma and NSCLC. RP3 dosing has commenced, and new data is expected in 2021. The company has successfully established a commercial-scale GMP manufacturing facility. Despite delays in patient enrollment due to COVID-19, Replimune maintains a strong cash position of $493 million, expected to fund operations through mid-2024.
Replimune Group, Inc. (NASDAQ: REPL) announced that CEO Philip Astley-Sparke will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 5:20 PM ET. The event will be held virtually, with a simultaneous webcast available on Replimune’s website. The presentation will focus on their innovative oncolytic immuno-gene therapies developed from the Immulytic™ platform, which aims to enhance cancer treatment by boosting immune responses to tumor antigens. A replay of the conference will be accessible for 30 days afterwards.
Replimune Group, Inc. (NASDAQ: REPL) announced the dosing of the first patient in a Phase 1 clinical trial for RP3, an oncolytic immuno-gene therapy. This trial will evaluate RP3 both alone and in combination with anti-PD-1 therapy in patients with advanced solid tumors. RP3 aims to enhance anti-tumor immune responses using a unique combination of immune-activating proteins. The trial focuses on safety, tolerability, and determining a recommended Phase 2 dose, with initial results expected later in 2021.
Replimune Group Inc. (Nasdaq: REPL) announced its senior management team's participation in investor meetings at the SVB Leerink Oncology 1x1 Day on November 19, 2020. The biotechnology company, based in Woburn, MA, focuses on developing oncolytic immuno-gene therapies from its Immulytic™ platform. This innovative approach aims to enhance cancer treatment by leveraging virus replication and immune response to tumor antigens. Replimune's goal is to advance these therapies through clinical development, working alongside other immuno-oncology treatments.
Replimune Group Inc. (NASDAQ: REPL) announced the availability of its posters for the Society for Immunotherapy of Cancer (SITC) annual meeting, held virtually from November 9-14, 2020. The company will actively participate in a press conference presenting updated results from its Phase 1/2 clinical trial of RP1, an oncolytic HSV combined with nivolumab. Two notable presentations include data from a Phase 1 trial of RP2 and updated results from skin cancer cohorts. Replimune focuses on developing oncolytic immuno-gene therapies to enhance cancer treatment efficacy.
FAQ
What is the current stock price of Replimune Group (REPL)?
What is the market cap of Replimune Group (REPL)?
